Head and Neck CancerEffEx-HNNCT05256238
Effect of Exercise in Head and Neck Cancer Patients
A study testing comprehensive supervised exercise program (CSEP) in people with Head and Neck Cancer, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.
Trial summary
Head and neck cancers (HNC) are malignancies originating from the mucosa in the oral cavity, nasopharynx, oropharynx, hypopharynx and larynx. Unfortunately, the majority of patients with HNC have locally advanced disease at diagnosis and should, therefore, be treated with chemoradiotherapy (CRT) or with radical… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Head and Neck Cancer
- What is being tested?
- comprehensive supervised exercise program (CSEP)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 133 participants
- Where
- 1 siteBelgium
- Study dates
- 25 Jan 2022to 23 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients ≥ 18 years
- Diagnosed with primary malignant tumour head and neck region (oral cavity, nasal cavity and paranasal sinuses, pharynx, larynx, salivary glands, thyroid)
- ECOG performance score 0-1
- Planned for curative (chemo)radiotherapy
- Able to complete baseline assessments prior to start of radiotherapy.
- Physically and mentally capable of taking part in an exercise program and motivated to engage in a supervised exercise program.
Who cannot join
- Patients < 18 years
- ECOG ≥ 2
- Patient with HNC, treated with palliative intent
- Evidence of distant metastases
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Improving Health-related Quality of Life of Head and Neck Cancer Patients Via a Dedicated Comprehensive Supervised Exercise Program (CSEP)
Head and neck cancers (HNC) are malignancies originating from the mucosa in the oral cavity, nasopharynx, oropharynx, hypopharynx and larynx. Unfortunately, the majority of patients with HNC have locally advanced disease at diagnosis and should, therefore, be treated with chemoradiotherapy (CRT) or with radical surgery followed by adjuvant (C)RT. Treatment of HNCs with (C)RT frequently results in serious and persistent impairments in physical and psychosocial functioning. In order to prevent worsening of a person's functioning at diagnoses and limit the physical impact of the treatments for HNC, a comprehensive supervised exercise program (CSEP) is needed early during treatment.
There is a need to improve integration of exercise programs into HNC care with aim to help head and neck cancer patients regain physical, mental and social functioning. Currently, no program is available adapted to the specific needs of head and neck cancer patients, in particular during cancer treatment.
Read more
The primary scientific objective is to examine the effectiveness of a comprehensive supervised exercise program, in addition to usual care, on health-related quality of life (primary outcome parameters) during treatment of head and neck cancer, compared to usual care only, up to 1 year after diagnosis.
Secondary objectives entail gathering information on the effectiveness of the CSEP, in addition to usual care on secondary outcome parameter such as physical and mental functioning, activity level and participation level; to determine the feasibility of such CSEP (defined as at least 50% of eligible patients enrolling in the study and completing at least 50% of the planned intervention sessions) and possible barriers and facilitators for participating in a CSEP during head and neck cancer treatment.
- Conditions
- Head and Neck Cancer
- Being tested
- comprehensive supervised exercise program (CSEP)
- Keywords
- exercise program
- Medical subject headings
- Head and Neck Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
comprehensive supervised exercise program (CSEP)Other
The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks:
- week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,…
- week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home
- maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation
| Study group | Role | What they receive |
|---|---|---|
| usual supportive care + comprehensive supervised exercise program (CSEP) | Experimental | Not described Receives: Other: comprehensive supervised exercise program (CSEP) |
| usual supportive care | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Health-related quality of life
Health-related quality of life will be measured with the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Measured: 6 months post-diagnosis
Secondary outcomes (23)
Health-related quality of life: physical functioning
The physical functioning subscale of the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) 6 months post-diagnosis is the key secondary outcome.
Measured: 6 months
Disease-specific health-related quality of life
Disease-specific health-related quality of life will be measured with the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC-QLQ-HN43). EORTC QLQ-HN43 module has 43 questions and is combined into 12 scales (Fear of Progression, Body Image, Dry Mouth and Sticky Saliva, Pain in the Mouth, Sexuality, Problems with Senses, Problems with Shoulder, Skin Problems, Social Eating, Speech, Swallowing and Problems with Teeth) and 7 single items (Coughing, Swelling in the Neck, Neurological Problems, Trismus, Social Contact, Weight Loss and Wound Healing). All of the scales and single-item measures range in score from 0 to 100. For all items and scales, high scores indicate more problems.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical function: Pain
Pain will be measured using the Brief Pain Inventory (questionnaire), a self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity, list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life on a 10 point scale.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical function: Fatigue
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function (questionnaire). FACIT-F scores range between 0 and 52, with higher scores indicating less fatigue.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Upper limb strength
A Jamar handheld dynamometer will be used to measure upper limb strength.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Lymphedema: neck circumference measurement
The presence of lymphedema will be evaluated with tape measurement of the neck circumference
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Lymphedema: %water content
%water content will be measured with the MoisturemeterD Compact (tissue dielectric constant (TDC) measurement)
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Lymphedema: self-reported
Self-reported lymphedema will be assessed with the Lymphedema Symptom Intensity and Distress Survey - Truncal and Head and Neck (LSIDS-H\&N).This tool was developed specifically to measure lymphedema symptoms in HNC patients. The tool asks participants to indicate the presence of a symptom (yes or no). Participants then rate all yes symptoms for intensity and distress on two separate 10-point numeric scales.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Shoulder forward flexion and abduction range of motion
The range of motion of both shoulder forward flexion and abduction will be measured using an inclinometer
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical fitness
The 6 minute walking distance (6MWD) will be used to evaluate physical fitness. This is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Body composition: amount of fat, bone, water, and muscle in the body
Body composition will be assessed through Bio-impedance Spectroscopy with InBody device. Bioelectrical Impedance Analysis (BIA) is a method of quantifying body composition by introducing an electrical current throughout the body. InBody uses this method to measure body composition, which divides the persons weight into different components, such as water, lean body mass and fat mass.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical functioning
The PROMIS physical function short form (PROMIS-PF-SF) (questionnaire) will be used to measure physical functioning. It is composed of 10, 5-point Likert-scale items. A higher PROMIS T-score represents more of the concept being measured.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Radiotherapy-related fibrosis
Medical Research Council Rating Scale for Fibrosis: 4-point rating scale ranging from none to very marked density, retraction, and fixation.
Measured: baseline- 6 weeks -12 weeks
Radiotherapy-related fibrosis
RTOG Late Radiation Morbidity Scoring Scheme : 0-4 scale with descriptors for each category. Health provider administered, based on patient symptoms: 0 - absence of radiation effects, 5 - effects led to death. Severity of reaction is graded from 1-4.
Measured: 6 months - 12 months
Depression, anxiety, stress
The Depression, Anxiety and Stress Scale-21 (DASS-21)(questionnaire) will be used. The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress.
The rating scale is as follows: 0 Did not apply to me at all- 1 Applied to me to some degree, or some of the time - 2 Applied to me to a considerable degree or a good part of time - 3 Applied to me very much or most of the time.
Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Self-efficacy
General Self-Efficacy Scale (questionnaire). This scale is a self-report measure of self-efficacy with 10 items (scored from 1-4). The total score is calculated by finding the sum of the all items. For the GSE, the total score ranges between 10 and 40, with a higher score indicating more self-efficacy.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Stage of readiness to change
The Physician-based Assessment and Counseling for Exercise (PACE) has 8 items intended to identify the patient's stage of readiness to begin a physical activity program.
Measured: baseline -12 weeks
Motivation towards exercise
Behavioral Regulation in Exercise Questionnaire 2 will be used to assess motivation towards exercise. The BREQ-2 is a 19 item questionnaire that measures the stages of the self-determination continuum with respect to motivation to exercise with a 5 point Likert scale (0=not true for me, 4=very true for me)
Measured: baseline -12 weeks
Upper limb function
The short version of the Disability of Arm, Shoulder and Hand - questionnaire will be used to evaluate upper limb function. The QuickDASH is a shortened version of the DASH Outcome Measure. Instead of 30 items, the QuickDASH uses 11 items to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. The resultant score is reported on a scale of 0 to 100, where 0 represents no disability and 100 represents total disability
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical activity level
Both the International Physical Activity Questionnaire and daily step count (accelerometry) will be used to determine the physical activity level.
The IPAQ is a 27-item self-reported measure of physical activity for use with individual adult patients aged 15 to 69 years old.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Social participation
Impact on Participation and Autonomy Questionnaire : The IPA is a questionnaire that focuses on autonomy and participation of people with chronic conditions. The perceived participation scale consists of 31 items which are assessed using a 5 point rating scale (1=very good and 5=very poor) and the problem scale contains 8 items which are assessed using a 3 point rating scale (0=no problem and 2=severe problem). A participation score (range: 30-155) and a problem score (0-16) are produced by summing items in each scale.
Measured: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Return to work
The subjects will be asked to report their return to work
Measured: baseline - 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Health-related quality of life
Health-related quality of life will be measured with the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Measured: baseline - 6 weeks -12 weeks- 12 months post-diagnosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2022
- Study start25 Jan 2022
- Primary completion23 Jun 2025
- Study completion23 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Head and Neck CancerStudies of the same condition, open and under way.
- More trials run by Universitaire Ziekenhuizen KU LeuvenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 133 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Sponsor type
- University, hospital or other
- Collaborators
- Kom Op Tegen Kanker
- Responsible party
- Sponsor
- Investigators
- Sandra Nuyts, Prof, Principal investigator, UZ/KU Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05256238
- Sponsor's protocol ID
- s65549
- Acronym
- EffEx-HN
- Status last verified
- Jan 2026
- First submitted
- 23 Nov 2021
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Van Aperen K, Nuyts S, Devoogdt N, Troosters T, De Vrieze T, Gursen C, De Groef A. Cross-cultural adaptation, validity and reliability of the Dutch version of the Lymphedema Symptom Intensity and Distress Survey-Head and Neck version 2.0 (LSIDS-H&N v2.0) in head and neck cancer patients. Disabil Rehabil. 2026 Feb;48(4):1125-1140. doi: 10.1080/09638288.2025.2554945. Epub 2025 Sep 7.
PubMed 40914813Van Aperen K, De Groef A, Troosters T, Elshout P, Nuyts S. Feasibility of a comprehensive supervised exercise program during and after treatment of head and neck cancer: a mixed-methods study. Support Care Cancer. 2025 Jan 16;33(2):107. doi: 10.1007/s00520-024-09112-y.
PubMed 39820655Van Aperen K, De Groef A, Devoogdt N, De Vrieze T, Troosters T, Bollen H, Nuyts S. EffEx-HN trial: study protocol for a randomized controlled trial on the EFFectiveness and feasibility of a comprehensive supervised EXercise program during radiotherapy in Head and Neck cancer patients on health-related quality of life. Trials. 2023 Apr 15;24(1):276. doi: 10.1186/s13063-023-07170-x.
PubMed 37061715
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Health-related Quality of Life of Head and Neck Cancer Patients Via a Dedicated Comprehensive Supervised Exercise Program (CSEP)
- ClinicalTrials.gov ID
- NCT05256238
- Acronym / sponsor ID
- EffEx-HN / s65549
- Conditions
- Head and Neck Cancer
- Keywords
- exercise program
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 133 participants (actual)
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenUniversity, hospital or other
- Collaborators
- Kom Op Tegen Kanker
- Study start
- 25 Jan 2022 (actual)
- Primary completion
- 23 Jun 2025 (actual)
- Study completion
- 23 Dec 2025 (actual)
- First posted
- 25 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Head and neck cancers (HNC) are malignancies originating from the mucosa in the oral cavity, nasopharynx, oropharynx, hypopharynx and larynx. Unfortunately, the majority of patients with HNC have locally advanced disease at diagnosis and should, therefore, be treated with chemoradiotherapy (CRT) or with radical surgery followed by adjuvant (C)RT. Treatment of HNCs with (C)RT frequently results in serious and persistent impairments in physical and psychosocial functioning. In order to prevent worsening of a person's functioning at diagnoses and limit the physical impact of the treatments for HNC, a comprehensive supervised exercise program (CSEP) is needed early during treatment.
There is a need to improve integration of exercise programs into HNC care with aim to help head and neck cancer patients regain physical, mental and social functioning. Currently, no program is available adapted to the specific needs of head and neck cancer patients, in particular during cancer treatment.
The primary scientific objective is to examine the effectiveness of a comprehensive supervised exercise program, in addition to usual care, on health-related quality of life (primary outcome parameters) during treatment of head and neck cancer, compared to usual care only, up to 1 year after diagnosis.
Secondary objectives entail gathering information on the effectiveness of the CSEP, in addition to usual care on secondary outcome parameter such as physical and mental functioning, activity level and participation level; to determine the feasibility of such CSEP (defined as at least 50% of eligible patients enrolling in the study and completing at least 50% of the planned intervention sessions) and possible barriers and facilitators for participating in a CSEP during head and neck cancer treatment.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| usual supportive care + comprehensive supervised exercise program (CSEP) | Experimental | Other: comprehensive supervised exercise program (CSEP) |
| usual supportive care | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients ≥ 18 years
- Diagnosed with primary malignant tumour head and neck region (oral cavity, nasal cavity and paranasal sinuses, pharynx, larynx, salivary glands, thyroid)
- ECOG performance score 0-1
- Planned for curative (chemo)radiotherapy
- Able to complete baseline assessments prior to start of radiotherapy.
Key exclusion criteria (4 listed)
- Patients < 18 years
- ECOG ≥ 2
- Patient with HNC, treated with palliative intent
- Evidence of distant metastases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| comprehensive supervised exercise program (CSEP)The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks: * week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,… * week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home * maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation | Other | usual supportive care + comprehensive supervised exercise program (CSEP) |
Primary outcome
Health-related quality of life
Time frame: 6 months post-diagnosis
Health-related quality of life will be measured with the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
23 secondary outcomes
Health-related quality of life: physical functioning
Time frame: 6 months
Disease-specific health-related quality of life
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical function: Pain
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical function: Fatigue
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Upper limb strength
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Lymphedema: neck circumference measurement
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Lymphedema: %water content
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Lymphedema: self-reported
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Shoulder forward flexion and abduction range of motion
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical fitness
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Body composition: amount of fat, bone, water, and muscle in the body
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical functioning
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Radiotherapy-related fibrosis
Time frame: baseline- 6 weeks -12 weeks
Radiotherapy-related fibrosis
Time frame: 6 months - 12 months
Depression, anxiety, stress
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Self-efficacy
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Stage of readiness to change
Time frame: baseline -12 weeks
Motivation towards exercise
Time frame: baseline -12 weeks
Upper limb function
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Physical activity level
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Social participation
Time frame: baseline- 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Return to work
Time frame: baseline - 6 weeks -12 weeks- 6 months - 12 months post-diagnosis
Health-related quality of life
Time frame: baseline - 6 weeks -12 weeks- 12 months post-diagnosis
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Derived from this study: PubMed 40914813Van Aperen K, Nuyts S, Devoogdt N, Troosters T, De Vrieze T, Gursen C, De Groef A. Cross-cultural adaptation, validity and reliability of the Dutch version of the Lymphedema Symptom Intensity and Distress Survey-Head and Neck version 2.0 (LSIDS-H&N v2.0) in head and neck cancer patients. Disabil Rehabil. 2026 Feb;48(4):1125-1140. doi: 10.1080/09638288.2025.2554945. Epub 2025 Sep 7.
- Derived from this study: PubMed 39820655Van Aperen K, De Groef A, Troosters T, Elshout P, Nuyts S. Feasibility of a comprehensive supervised exercise program during and after treatment of head and neck cancer: a mixed-methods study. Support Care Cancer. 2025 Jan 16;33(2):107. doi: 10.1007/s00520-024-09112-y.
- Derived from this study: PubMed 37061715Van Aperen K, De Groef A, Devoogdt N, De Vrieze T, Troosters T, Bollen H, Nuyts S. EffEx-HN trial: study protocol for a randomized controlled trial on the EFFectiveness and feasibility of a comprehensive supervised EXercise program during radiotherapy in Head and Neck cancer patients on health-related quality of life. Trials. 2023 Apr 15;24(1):276. doi: 10.1186/s13063-023-07170-x.
Related trials for Head and Neck Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sandra Nuyts, Prof principal investigator
UZ/KU Leuven
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing comprehensive supervised exercise program (CSEP) in people with Head and Neck Cancer, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Health-related quality of life (time frame: 6 months post-diagnosis). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05256238, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.